These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 2242412)

  • 21. A model-based approach in the estimation of the maximum tolerated dose in phase I cancer clinical trials.
    He W; Liu J; Binkowitz B; Quan H
    Stat Med; 2006 Jun; 25(12):2027-42. PubMed ID: 16025542
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design and analysis of phase I clinical trials.
    Storer BE
    Biometrics; 1989 Sep; 45(3):925-37. PubMed ID: 2790129
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Measurement of botulinum toxin activity: evaluation of the lethality assay.
    Pearce LB; Borodic GE; First ER; MacCallum RD
    Toxicol Appl Pharmacol; 1994 Sep; 128(1):69-77. PubMed ID: 8079356
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Regulatory cancer risk assessment based on a quick estimate of a benchmark dose derived from the maximum tolerated dose.
    Gaylor DW; Swirsky Gold L
    Regul Toxicol Pharmacol; 1998 Dec; 28(3):222-5. PubMed ID: 10049793
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Calculation of carcinogenic potency from long-term animal carcinogenesis experiments.
    Sawyer C; Peto R; Bernstein L; Pike MC
    Biometrics; 1984 Mar; 40(1):27-40. PubMed ID: 6733232
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparing experimental designs for benchmark dose calculations for continuous endpoints.
    Kuljus K; von Rosen D; Sand S; Victorin K
    Risk Anal; 2006 Aug; 26(4):1031-43. PubMed ID: 16948695
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An adaptive dose-finding design incorporating both toxicity and efficacy.
    Zhang W; Sargent DJ; Mandrekar S
    Stat Med; 2006 Jul; 25(14):2365-83. PubMed ID: 16220478
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Threshold dose-response models in toxicology.
    Cox C
    Biometrics; 1987 Sep; 43(3):511-23. PubMed ID: 3663815
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multiplicity-adjusted inferences in risk assessment: benchmark analysis with quantal response data.
    Nitcheva DK; Piegorsch WW; West RW; Kodell RL
    Biometrics; 2005 Mar; 61(1):277-86. PubMed ID: 15737104
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Designs for single- or multiple-agent phase I trials.
    Conaway MR; Dunbar S; Peddada SD
    Biometrics; 2004 Sep; 60(3):661-9. PubMed ID: 15339288
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interpreting plots of a multidimensional dose-response surface in a parallel coordinate system.
    Gennings C; Dawson KS; Carter WH; Myers RH
    Biometrics; 1990 Sep; 46(3):719-35. PubMed ID: 2242411
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adaptive designs for dose-finding in non-cancer phase II trials: influence of early unexpected outcomes.
    Resche-Rigon M; Zohar S; Chevret S
    Clin Trials; 2008; 5(6):595-606. PubMed ID: 19029208
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Advances in and limitations of up-and-down methodology: a précis of clinical use, study design, and dose estimation in anesthesia research.
    Pace NL; Stylianou MP
    Anesthesiology; 2007 Jul; 107(1):144-52. PubMed ID: 17585226
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A generalization of the probit and logit methods for dose response curves.
    Prentice RL
    Biometrics; 1976 Dec; 32(4):761-8. PubMed ID: 1009225
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A parametric model for detecting hormetic effects in developmental toxicity studies.
    Hunt DL; Bowman D
    Risk Anal; 2004 Feb; 24(1):65-72. PubMed ID: 15028001
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The median lethal dose and its estimation.
    Finney DJ
    Arch Toxicol; 1985 Feb; 56(4):215-8. PubMed ID: 3994505
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rapid and accurate determination of the median lethal dose (LD50) and its error with a small computer.
    Rosiello AP; Essignmann JM; Wogan GN
    J Toxicol Environ Health; 1977 Dec; 3(5-6):797-809. PubMed ID: 599579
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Small-sample confidence limits for parameters under inequality constraints with application to quantal bioassay.
    Morris MD
    Biometrics; 1988 Dec; 44(4):1083-92. PubMed ID: 3233247
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of incomplete knowledge of parameter values on single- and multiple-stage designs for logistic regression.
    Spears FM; Brown BW; Atkinson EN
    Biometrics; 1997 Mar; 53(1):1-10. PubMed ID: 9147586
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Global comparison of radiation and chemotherapy dose-response curves with a test for interaction.
    Lindstrom MJ; Kunugi KA; Kinsella TJ
    Radiat Res; 1993 Aug; 135(2):269-77. PubMed ID: 7690150
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.